Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced results from its Phase 2 study of suzetrigine for painful ...

Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ...

Sciatica-related lower back pain is a common problem ... “Sciatica is a frequently used term for lumbar radiculopathy or a ...

Vertex Pharmaceuticals' suzetrigine shows promising results in treating painful lumbosacral radiculopathy, but stock falls ...

Vertex stock plummeted Thursday after the company's non-opioid pain drug proved it's no better than a placebo in patients ...

Vertex Pharmaceuticals Inc.’s non-addictive drug helped patients with lower back pain, moving the company closer to selling an alternative to opioids in another type of pain.

Vertex Pharmaceuticals shares fell after the company reported mixed results from a study of a treatment for patients with lumbosacral radiculopathy, a neurological disorder that causes back and leg ...

For 12 weeks, the study followed more than 200 patients with lumbosacral radiculopathy, a nerve condition in the lower back ...

Vertex Pharmaceuticals’ investigational non-opioid analgesic suzetrigine failed to outperform placebo. Investors voiced their ...

Treatment with the highly selective NaV1.8 pain signal inhibitor suzetrigine met the primary endpoint with a statistically significant and clinically ...

The sacroiliac joint is a common source of chronic lower back pain and a novel RFA-based ... Dorsal root ganglion RFA is used to treat radiculopathy. There are multiple applications of pulsed ...

I wouldn’t recommend Kirby to anyone. We also use the robots, because of my lower back issues: DDD, Sciatica, Radiculopathy, Lumbar Spondylosis with the occasional herniated or bulging disc all ...